DDMAC to Scios: Halt distribution of Natrecor promo materials

Share this article:
DDMAC to Scios: Halt distribution of Natrecor promo materials
DDMAC to Scios: Halt distribution of Natrecor promo materials

The FDA's Division of Drug Marketing, Advertising and Communications (DDMAC) has told Johnson & Johnson's Scios unit to stop distributing promotional computer mousepads and pens to physicians for its heart failure drug Natrecor.

In a letter sent to Scios, the FDA said the mousepads and pens list the drug's name and depict a man sitting in a hospital bed with water up to his shoulders.

“Simply put, the image evokes the concept of a sedentary hospital patient drowning,” DDMAC's regulatory review officer Lisa Hubbard said in the letter. The combination of the image with the Natrecor logo suggests that “Natrecor is indicated for seriously ill patients who have difficulty breathing while at rest because of fluid accumulation within the lungs,” Hubbard wrote.
 
Because the promotional materials “fail” to include the drug's indication and information regarding risk associated with Natrecor, DDMAC said it has determined the pieces “misbrand” Natrecor.
 
DDMAC requested that Scios stop distributing the promotional materials and urged the drugmaker to respond to the agency in writing by Nov. 21.

Scios spokesperson Chris Ernst said in a published report the company will contact the FDA about the best way to resolve the pen and mouse pad complaint.
 
"We will be cooperating with the agency," Ernst said, adding that "it was a pretty small quantity" of pens and pads that were given to doctors over "just a few months."

Share this article:

Email Newsletters

More in News

Lilly takes on Amgen's Enbrel

Lilly takes on Amgen's Enbrel

Phase-III tests indicate Lilly's experimental treatment bests Amgen's for moderate-to-severe plaque psoriasis.

GSK Ellipta franchise expands

GSK Ellipta franchise expands

The FDA has approved Arnuity Ellipta for asthma.

Five things for pharma marketers to know: Thursday, August 21

Five things for pharma marketers to know: Thursday, ...

An Ebola survivor is set to leave Emory University Hospital, but the cause of the cure is uncertain, the FDA has approved a new type 1 diabetes test, and the ...